Manufacturing

Innovative solutions are making personalized cell and gene therapies accessible to all.

Under a pilot program initiative introduced by the Biden administration, Aaron Cowley, chief scientific officer, ReciBioPharm, talked about the ongoing progress in developing continuous manufacturing for mRNA.

This podcast explores the challenges of and the progress made so far by the biopharma industry toward alternative drug delivering methods for biologic drugs.

Stable cell line development can benefit from applying integrated analytical technologies.

Bringing promising ADC candidates to market faster hinges on the biopharma industry investing in linker design capabilities.

Under the long-term supply agreement, Lonza will manufacture CASGEVY (exagamglogene autotemcel) for Vertex at its facility in Geleen, the Netherlands, and plans to expand manufacturing to Portsmouth, NH, in the United States.

The latest developments in emerging therapies, including new innovations and collaborative efforts in manufacturing.

Ecolab's Hayley Crowe, executive vice-president and general manager Global Life Sciences sat down at BIO 2024 to discuss technology innovations and how they have enhanced downstream bioprocessing.

Lilly has increased its manufacturing investment for biologics in Limerick, Ireland, by $1 billion while launching its new $800 million facility in Kinsale.

During a presentation at the PDA/FDA Joint Regulatory Conference, Nicholas Violand of Johnson & Johnson and Paul Palmer of Paul R. Palmer Limited discussed how aging facilities can impact the quality of pharmaceutical products.

The new Vivaflow SU tangential flow filtration cassette is designed to be more flexible and user-friendly and offers enhanced ultrafiltration and diafiltration efficiency.

This case study describes how the risk assessment of the first-to-market single-use disc-stack centrifuge was conducted.

Platform processes and effective risk assessments help overcome time and cost challenges.

Viral vectors and other complex biologic modalities require more specificity and higher sensitivity to detect and distinguish contaminants.

Rentschler Biopharma now offers a new lentiviral vector manufacturing toolbox at its site in Stevenage, UK.

A coordinated and international response is needed to help control the latest mpox outbreak in Africa.

Christian Cobaugh, CEO and founder of Vernal Biosciences, considers the outsourcing landscape for mRNA production.

Downstream processes may be streamlined by using automation.

Genentech will leverage Sangamo’s proprietary capsid delivery platform and epigenetic regulation capabilities to develop genomic medicines to address certain neurodegenerative diseases.

Under the license agreement, Andelyin Biosciences will expand its AAV Curator Platform by including MyoAAV plasmids developed by Broad Institute of MIT and Harvard.

Automation technologies used in the development and manufacture of biopharmaceuticals continue to evolve, providing the potential for reduced costs and time.

Optimizing AAV vector manufacturing will be necessary to meet anticipated future market demand.

With a $15 million fund-raising goal, US Specialty Formulations plans to invest in expanding its biopharma facility in Allentown, Pa.

AAV and lentivirus both have pros and cons in their use for specific gene therapy applications.

The biopharma industry is seeking ways to apply cell and gene therapies to mass patient populations.